Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2003 1
2004 1
2005 1
2006 2
2007 1
2008 2
2010 1
2014 1
2016 3
2017 5
2018 1
2019 1
2020 4
2021 5
2022 4
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean aramco (1,516 results)?
Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial.
Ratziu V, de Guevara L, Safadi R, Poordad F, Fuster F, Flores-Figueroa J, Arrese M, Fracanzani AL, Ben Bashat D, Lackner K, Gorfine T, Kadosh S, Oren R, Halperin M, Hayardeny L, Loomba R, Friedman S; ARREST investigator study group; Sanyal AJ. Ratziu V, et al. Nat Med. 2021 Oct;27(10):1825-1835. doi: 10.1038/s41591-021-01495-3. Epub 2021 Oct 7. Nat Med. 2021. PMID: 34621052 Free article. Clinical Trial.
ARREST, a 52-week, double-blind, placebo-controlled, phase 2b trial randomized 247 patients with NASH (n = 101, n = 98 and n = 48 in the Aramchol 400 mg, 600 mg and placebo arms, respectively; NCT02279524 ). ...Early termination due to adverse events (AEs) was <5%, and …
ARREST, a 52-week, double-blind, placebo-controlled, phase 2b trial randomized 247 patients with NASH (n = 101, n = 98 and n = 48 in the …
Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis.
Bhattacharya D, Basta B, Mato JM, Craig A, Fernández-Ramos D, Lopitz-Otsoa F, Tsvirkun D, Hayardeny L, Chandar V, Schwartz RE, Villanueva A, Friedman SL. Bhattacharya D, et al. JHEP Rep. 2021 Jan 28;3(3):100237. doi: 10.1016/j.jhepr.2021.100237. eCollection 2021 Jun. JHEP Rep. 2021. PMID: 34151243 Free PMC article.
Secretion of collagen 1 (Col1alpha1) was inhibited by 10 muM Aramchol. SCD1 knockdown in LX-2 cells phenocopied the effect of Aramchol by reducing fibrogenesis, and addition of Aramchol to these cells did not rescue fibrogenic gene expression. ...In phHeps, …
Secretion of collagen 1 (Col1alpha1) was inhibited by 10 muM Aramchol. SCD1 knockdown in LX-2 cells phenocopied the effect of Aram …
Current and future pharmacological therapies for NAFLD/NASH.
Sumida Y, Yoneda M. Sumida Y, et al. J Gastroenterol. 2018 Mar;53(3):362-376. doi: 10.1007/s00535-017-1415-1. Epub 2017 Dec 16. J Gastroenterol. 2018. PMID: 29247356 Free PMC article. Review.
., pemafibrate, elafibranor), medications targeting farnesoid X receptor axis [obeticholic acid; OCA)], inhibitors of de novo lipogenesis (aramchol, ACC inhibitor), and fibroblast growth factor-21 analogues. ...
., pemafibrate, elafibranor), medications targeting farnesoid X receptor axis [obeticholic acid; OCA)], inhibitors of de novo lipogenesis ( …
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH.
Tacke F, Puengel T, Loomba R, Friedman SL. Tacke F, et al. J Hepatol. 2023 Aug;79(2):552-566. doi: 10.1016/j.jhep.2023.03.038. Epub 2023 Apr 14. J Hepatol. 2023. PMID: 37061196 Review.
Targets for reducing the activation of inflammatory cascades include nuclear receptor agonists (e.g. resmetirom, lanifibranor, obeticholic acid), modulators of lipotoxicity (e.g. aramchol, acetyl-CoA carboxylase inhibitors) or modification of genetic variants (e.g. ...
Targets for reducing the activation of inflammatory cascades include nuclear receptor agonists (e.g. resmetirom, lanifibranor, obeticholic a …
Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease.
Fraile JM, Palliyil S, Barelle C, Porter AJ, Kovaleva M. Fraile JM, et al. Drug Des Devel Ther. 2021 Sep 22;15:3997-4009. doi: 10.2147/DDDT.S315724. eCollection 2021. Drug Des Devel Ther. 2021. PMID: 34588764 Free PMC article. Review.
Obeticholic acid (Intercept Pharmaceuticals), Cenicriviroc (Allergan), Aramchol (Galmed Pharmaceuticals), Resmetirom (Madrigal Pharmaceuticals), Dapagliflozin and Semaglutide (Novo Nordisk) are in advanced Phase 3 clinical trials, while Belapectin (Galectin Therapeutics), …
Obeticholic acid (Intercept Pharmaceuticals), Cenicriviroc (Allergan), Aramchol (Galmed Pharmaceuticals), Resmetirom (Madrigal Pharma …
Role of Aramchol in steatohepatitis and fibrosis in mice.
Iruarrizaga-Lejarreta M, Varela-Rey M, Fernández-Ramos D, Martínez-Arranz I, Delgado TC, Simon J, Juan VG, delaCruz-Villar L, Azkargorta M, Lavin JL, Mayo R, Van Liempd SM, Aurrekoetxea I, Buqué X, Cave DD, Peña A, Rodríguez-Cuesta J, Aransay AM, Elortza F, Falcón-Pérez JM, Aspichueta P, Hayardeny L, Noureddin M, Sanyal AJ, Alonso C, Anguita J, Martínez-Chantar ML, Lu SC, Mato JM. Iruarrizaga-Lejarreta M, et al. Hepatol Commun. 2017 Nov;1(9):911-927. doi: 10.1002/hep4.1107. Epub 2017 Oct 4. Hepatol Commun. 2017. PMID: 29159325 Free PMC article.
Aramchol administration reduced features of steatohepatitis and fibrosis in 0.1MCD fed mice. Aramchol downregulated stearoyl-CoA desaturase 1 (SCD1), a key enzyme involved in triglyceride biosynthesis whose loss enhances fatty acid beta-oxidation. ...
Aramchol administration reduced features of steatohepatitis and fibrosis in 0.1MCD fed mice. Aramchol downregulated stearoyl-C …
Effects of Aramchol in patients with nonalcoholic fatty liver disease (NAFLD). A systematic review and meta-analysis.
Malik A, Nadeem M, Amjad W, Malik MI, Javaid S, Farooq U, Naseem K, Khan A. Malik A, et al. Prz Gastroenterol. 2023;18(1):67-75. doi: 10.5114/pg.2022.113573. Epub 2022 Feb 17. Prz Gastroenterol. 2023. PMID: 37007760 Free PMC article.
There is little evidence supporting its efficacy in humans. AIM: To evaluate the efficacy of Aramchol in patients with NAFLD according to different randomized clinical trials. ...AST levels were significantly higher in the Aramchol group (MD =11.04 (4.91, 17.16), p …
There is little evidence supporting its efficacy in humans. AIM: To evaluate the efficacy of Aramchol in patients with NAFLD accordin …
URI alleviates tyrosine kinase inhibitors-induced ferroptosis by reprogramming lipid metabolism in p53 wild-type liver cancers.
Ding Z, Pan Y, Shang T, Jiang T, Lin Y, Yang C, Pang S, Cui X, Wang Y, Feng XF, Xu M, Pei M, Chen Y, Li X, Ding J, Tan Y, Wang H, Dong L, Wang L. Ding Z, et al. Nat Commun. 2023 Oct 7;14(1):6269. doi: 10.1038/s41467-023-41852-z. Nat Commun. 2023. PMID: 37805657 Free PMC article.
High expression of URI is correlated with high level of SCD1 and their synergetic expression predicts poor prognosis and TKIs resistance in HCC. The combination of SCD1 inhibitor aramchol and deuterated sorafenib derivative donafenib displays promising anti-tumor effects i …
High expression of URI is correlated with high level of SCD1 and their synergetic expression predicts poor prognosis and TKIs resistance in …
The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease.
Safadi R, Konikoff FM, Mahamid M, Zelber-Sagi S, Halpern M, Gilat T, Oren R; FLORA Group. Safadi R, et al. Clin Gastroenterol Hepatol. 2014 Dec;12(12):2085-91.e1. doi: 10.1016/j.cgh.2014.04.038. Epub 2014 May 9. Clin Gastroenterol Hepatol. 2014. PMID: 24815326 Free article. Clinical Trial.
Liver fat content decreased in the 100-mg Aramchol group, by 2.89% 28.22%, but this change was nonsignificant (P = .35), indicating a dose-response relationship (P for trend = .01). ...CONCLUSIONS: Three months' administration of the fatty acid-bile acid conjugate Aramc …
Liver fat content decreased in the 100-mg Aramchol group, by 2.89% 28.22%, but this change was nonsignificant (P = .35), indicating a …
Novel Pharmacotherapy Options for NASH.
Ratziu V. Ratziu V. Dig Dis Sci. 2016 May;61(5):1398-405. doi: 10.1007/s10620-016-4128-z. Epub 2016 Mar 22. Dig Dis Sci. 2016. PMID: 27003143 Review.
Meanwhile, other compounds are being tested, a few in phase 2b studies (cenicriviroc, aramchol for NASH, and simtuzumab for NASH fibrosis) and many more in earlier, smaller trials. ...
Meanwhile, other compounds are being tested, a few in phase 2b studies (cenicriviroc, aramchol for NASH, and simtuzumab for NASH fibr …
33 results